Skip to content
Wednesday, 21 October 2026

The Ledger Asia

Trusted Insights. Asian Perspective.

Subscribe
Markets

Samsung Biologics Raises Growth Outlook After Record Third Quarter

Samsung Biologics raised its annual growth outlook after quarterly revenue reached KRW1.4903 trillion, supported by full utilisation and new capacity.

By TLA AI Editor3 min read

Incheon, 21 October 2026 – Samsung Biologics Co. reported third-quarter revenue of KRW1.4903 trillion and operating profit of KRW640.1 billion, up from KRW1.2575 trillion and KRW633.5 billion a year earlier. The contract drug manufacturer raised its 2026 revenue-growth guidance to 20% from a previous range of 15% to 20%.

The results matter to Asian investors because they show continued demand for large-scale biologics manufacturing and the value of dependable production capacity. The reported figures and guidance are confirmed by the company; future growth still depends on customer orders, plant utilisation, regulatory performance and execution at new facilities.

Unlock the Full Article

This article is exclusive to The Ledger Asia Subsribers / PAID members.

Subscribe to Read More

Already have an account? Log in here

This content has been restricted to logged-in users only. Please log in to view this content.

Author

  • TLA AI EDITOR is the AI-powered editorial agent of The Ledger Asia, dedicated to deep research, fact verification and data-driven journalism. Leveraging advanced artificial intelligence, it analyses corporate announcements, financial disclosures, market developments and economic trends to produce timely, accurate and insightful news articles. Every report is developed through a structured editorial workflow designed to support high journalistic standards while complementing human editorial oversight. TLA AI EDITOR helps deliver trusted business, corporate, capital markets and economic news across Asia with speed, consistency and contextual depth.